PMID- 27595481
OWN - NLM
STAT- MEDLINE
DCOM- 20180803
LR  - 20180803
IS  - 1421-9751 (Electronic)
IS  - 0008-6312 (Linking)
VI  - 136
IP  - 2
DP  - 2017
TI  - Comparison of Long-Term Outcome between Apical and Asymmetric Septal Hypertrophic 
      Cardiomyopathy.
PG  - 108-114
LID - 10.1159/000448239 [doi]
AB  - OBJECTIVES: As reported, diagnostic age, gender and presence of outflow tract 
      obstruction have an impact on prognosis in patients with hypertrophic 
      cardiomyopathy. The aim of this study was to compare the long-term outcome 
      between apical hypertrophic cardiomyopathy (ApHCM) and asymmetric septal 
      hypertrophic cardiomyopathy (ASHCM) after the exclusion of these factors. 
      METHODS: A total of 540 patients (270 with ApHCM and 270 with ASHCM) identified 
      in a consecutive single-center cohort were retrospectively studied. The two 
      groups were matched by diagnostic age, gender and the presence of outflow tract 
      obstruction. Clinical characteristics and long-term outcomes were compared. 
      RESULTS: The mean follow-up duration in ASHCM and ApHCM were 6.6 +/- 5.5 and 7.6 +/- 
      4.1 years, respectively. During follow-up, 16 patients experienced cardiovascular 
      death in the ASHCM group, while 2 patients experienced cardiovascular death in 
      the ApHCM group (6.3 vs. 0.7%, p < 0.01). Cardiovascular morbidity in the ASHCM 
      and ApHCM groups were 39.9 and 18.5% (p < 0.01). In the multivariate Cox 
      regression analysis late gadolinium enhancement (LGE; HR 4.81, 95% CI 1.28-78.0, 
      p = 0.03) and unexplained syncope (HR 9.68, 95% CI 1.9-17.2, p < 0.01) were 
      independent predictors for cardiovascular mortality. Unexplained syncope was 
      independently associated with a higher risk for sudden cardiac death (HR 4.3, 95% 
      CI 1.2-15.3, p = 0.02). CONCLUSIONS: After eliminating the interference of 
      diagnostic age, gender and outflow tract obstruction, ASHCM represented a worse 
      prognosis with a higher incidence of cardiovascular mortality and morbidity than 
      ApHCM. LGE was a strong predictor for cardiovascular death.
CI  - (c) 2016 S. Karger AG, Basel.
FAU - An, Shuoyan
AU  - An S
AD  - Key Laboratory of Clinical Trial Research in Cardiovascular Drugs, Ministry of 
      Health, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
FAU - Fan, Chaomei
AU  - Fan C
FAU - Yan, Lirong
AU  - Yan L
FAU - Cai, Chi
AU  - Cai C
FAU - Yang, Yinjian
AU  - Yang Y
FAU - Zhai, Shanshan
AU  - Zhai S
FAU - Zhao, Shihua
AU  - Zhao S
FAU - Liu, Yanling
AU  - Liu Y
FAU - Duan, Fujian
AU  - Duan F
FAU - Wang, Zhimin
AU  - Wang Z
FAU - Li, Yishi
AU  - Li Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20160906
PL  - Switzerland
TA  - Cardiology
JT  - Cardiology
JID - 1266406
SB  - IM
MH  - Adult
MH  - Cardiomyopathy, Hypertrophic/*complications/mortality/pathology
MH  - Cardiovascular Diseases/epidemiology/mortality
MH  - Death, Sudden, Cardiac/etiology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Syncope/etiology
EDAT- 2016/09/07 06:00
MHDA- 2018/08/04 06:00
CRDT- 2016/09/06 06:00
PHST- 2016/06/16 00:00 [received]
PHST- 2016/07/07 00:00 [accepted]
PHST- 2016/09/07 06:00 [pubmed]
PHST- 2018/08/04 06:00 [medline]
PHST- 2016/09/06 06:00 [entrez]
AID - 000448239 [pii]
AID - 10.1159/000448239 [doi]
PST - ppublish
SO  - Cardiology. 2017;136(2):108-114. doi: 10.1159/000448239. Epub 2016 Sep 6.